First Histotripsy Clinical Trial
A first-in-human clinical trial – the “THERESA” study – took place at three sites in Barcelona, Spain, under the direction of Joan Vidal-Jové, MD, PhD, Head of Focused Ultrasound Ablation Oncology at Barcelona University Hospital.
Eight enrolled patients, ages 46 to 87 years, underwent general anesthesia prior to receiving histotripsy ablation to a total of 11 liver lesions, which ranged in size from 0.5 to 2.1 cm (average 1.3 cm). All patients suffered from primary or multifocal liver metastases with the following primary tumors: colorectal cancer (5 patients), gallbladder carcinoma (1 patients), hepatocellular carcinoma (1 patient), and breast cancer (1 patient).